Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need

Caris Life Sciences announced that its therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech to identify and validate novel oncology targets in solid tumor tissue, aiming to address cancers with high unmet clinical need. Under the terms of the agreement, Caris is eligible for an upfront and near-term $25 million payment and could receive up to $1.1 billion in research, development, commercial, and sales milestone payments, as well as potential tiered royalties on any resulting therapies. By combining Caris’ extensive multimodal molecular data and tissue-based discovery engine with Genentech’s therapeutic development capabilities, the partnership seeks to advance first-in-class medicines for cancer patients.

Learn More